The deal delivers $375 million in non-dilutive capital structured around capped royalty payments, alongside a $25 million equity investment. Oberland Capital will provide an initial $135 million immediately, with subsequent funding tranches contingent upon positive clinical data readouts and the successful progression of regulatory approvals for MeiraGTx’s in-development portfolio.
In section Market Quotes
MeiraGTx Secures $400 Million Funding Boost from Oberland Capital
With three late-stage genetic medicines nearing potential regulatory approval, MeiraGTx has finalized a $400 million financing agreement with Oberland Capital Management. This infusion of capital aims to accelerate the company’s commercialization efforts while providing the financial runway necessary to bring its diverse pipeline of therapies to market.
Michael Bloom, a partner at Oberland Capital, pointed to the company’s near-term pipeline—specifically three therapies expected to reach approval within two years—as the primary driver for the investment. Following the announcement, MeiraGTx shares rose 4.4% to $14.50 in premarket trading. CEO Alexandria Forbes noted that the multi-product structure allows the firm to secure substantial liquidity without sacrificing long-term business development flexibility.
Comments (0)
No comments yet. Be the first!